Rivastigmine Tartrate Solid Lipid Nanoparticles Loaded Transdermal Film:An In vivo Study

In the present investigation, Rivastigmine Tartrate incorporated solid lipid nanoparticles (SLN) films were made to enhance its uptake to brain via systemic circulation. SLN were prepared by modified emulsification diffusion method and SLN’s loaded transdermal films were prepared by solvent casting method. The optimized Rivastigmine Tartrate SLN loaded formulation was evaluated for pharmacokinetic study and dermal toxicity study. In vivo studies were performed on New Zealand white rabbits and various pharmacokinetic and dermal toxicity parameters were determined. The pharmacokinetic parameters after administration of Rivastigmine Tartrate loaded SLN film were found to be, T_max 3 h, C_max 116.17 ± 1.5 ng/mL, AUC_{0 - ∞} 1848.29±4.87 ng.h/mL, and K_e 0.18 ± 0.028 h^-1. The dermal toxicity study was carried out for 3 min, 1 h and 4 h respectively with optimized film and no skin irritation or redness was found. The results highlights that the prepared formulation of SLN loaded films were able to deliver a sustained supply of the Rivastigmine Tartrate.